Guideline: Spanish Language Translations

Manejo Inicial del Cáncer de Próstata Sensible a la Castración Avanzado, Recurrente o Metastásico

Guideline Status: Current

Published Online: April 3, 2023

Last Updated: August 1, 2023

Publicado antes de su impresión el 3 de abril de 2023, DOI: 1200/JCO.23.00155

Katherine S. Virgo, R. Bryan Rumble, y James Talcott.

Objetivo

Actualizar todas las guías ASCO anteriores en función de la discusión y los ensayos de terapia de triplete.

Metodología

Este producto de guía basado en la revisión sistemática fue desarrollado por un panel de expertos multidisciplinario, que incluyó un representante del paciente y un miembro del personal de las guías ASCO con experiencia en metodología de investigación en salud.

Resultados

Seis artículos, incluido un metaanálisis y un metaanálisis de la red, fundamentaron esta actualización de la guía.

Recomendaciones

Docetaxel, abiraterona, enzalutamida, apalutamida o darolutamida, cada uno cuando se administra con ADT, representan cinco SoC separados para el cáncer de próstata metastásico sensible a la castración. Con la excepción de las terapias de triplete de docetaxel más abiraterona más ADT y docetaxel más darolutamida más ADT, el uso de cualquiera de estos agentes en cualquier otra combinación particular o en cualquier serie particular aún no se puede recomendar.

© (2023) American Society of Clinical Oncology, todos los derechos reservados. Para conocer las oportunidades de licencia, comuníquese con licensing@asco.org

Guideline Disclaimer

The clinical practice guidelines and other guidance published herein are provided by the American Society of Clinical Oncology, Inc. ("ASCO") to assist practitioners in clinical decision making. The information therein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating physician, as the information does not account for individual variation among patients. Recommendations reflect high, moderate or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like "must," "must not," "should," and "should not" indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating physician in the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an "as is" basis, and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions